NeurAxis to Host Third Quarter 2024 Results and Business Update Call on Tuesday, November 12, 2024
NeurAxis (NYSE American: NRXS), a medical technology company focused on neuromodulation therapies for chronic conditions, has scheduled its Q3 2024 earnings call for Tuesday, November 12, 2024, at 9:00 AM ET. The company will release its financial results for the quarter ended September 30, 2024, before the market opens.
Stakeholders can participate through a live webcast available on the company's investor relations website, with options to submit questions through the portal or via email. A conference call option is also available for participants who register in advance, and a replay will be accessible on the company's website.
NeurAxis (NYSE American: NRXS), un'azienda tecnologica medica focalizzata sulle terapie di neuromodulazione per condizioni croniche, ha programmato la sua call sugli utili del Q3 2024 per martedì 12 novembre 2024, alle 9:00 ET. L'azienda pubblicherà i risultati finanziari per il trimestre concluso il 30 settembre 2024, prima dell'apertura del mercato.
Gli interessati possono partecipare tramite un webcast in diretta disponibile sul sito web delle relazioni con gli investitori dell'azienda, con possibilità di inviare domande tramite il portale o via email. È inoltre disponibile un'opzione di conferenza telefonica per i partecipanti che si registrano in anticipo, e una registrazione sarà accessibile sul sito web dell'azienda.
NeurAxis (NYSE American: NRXS), una empresa de tecnología médica centrada en terapias de neuromodulación para condiciones crónicas, ha programado su llamada de ganancias del Q3 2024 para el martes 12 de noviembre de 2024, a las 9:00 AM ET. La empresa publicará sus resultados financieros para el trimestre que finalizó el 30 de septiembre de 2024, antes de la apertura del mercado.
Los interesados pueden participar a través de un webcast en vivo disponible en el sitio web de relaciones con inversores de la empresa, con opciones para enviar preguntas a través del portal o por correo electrónico. También hay una opción de llamada de conferencia disponible para los participantes que se registren con antelación, y una repetición estará accesible en el sitio web de la empresa.
NeurAxis (NYSE American: NRXS)는 만성 질환을 위한 신경 조절 치료에 중점을 둔 의료 기술 회사로, 2024년 3분기 실적 발표 전화 회의를 2024년 11월 12일 화요일 오전 9시(ET)에 예정하고 있습니다. 이 회사는 2024년 9월 30일로 종료된 분기의 재무 결과를 시장 개장 전에 발표할 예정입니다.
이해관계자는 회사의 투자자 관계 웹사이트에서 제공되는 실시간 웹캐스트를 통해 참여할 수 있으며, 포털이나 이메일을 통해 질문을 제출할 수 있는 옵션도 있습니다. 사전에 등록한 참가자를 위한 전화 회의 옵션도 제공되며, 재생은 회사 웹사이트에서 이용할 수 있습니다.
NeurAxis (NYSE American: NRXS), une entreprise de technologie médicale axée sur les thérapies de neuromodulation pour des conditions chroniques, a programmé sa conférence téléphonique sur les résultats du T3 2024 pour le mardi 12 novembre 2024, à 9h00 ET. L'entreprise publiera ses résultats financiers pour le trimestre clos le 30 septembre 2024, avant l'ouverture des marchés.
Les parties prenantes peuvent participer via un webinaire en direct disponible sur le site web des relations investisseurs de l'entreprise, avec la possibilité de soumettre des questions via le portail ou par e-mail. Une option de conférence téléphonique est également disponible pour les participants qui s'inscrivent à l'avance, et un replay sera accessible sur le site web de l'entreprise.
NeurAxis (NYSE American: NRXS), ein Medizintechnologieunternehmen, das sich auf Neuromodulationstherapien für chronische Erkrankungen konzentriert, hat seine Telefonkonferenz zu den Q3 2024-Ergebnissen für Dienstag, den 12. November 2024, um 9:00 Uhr ET angesetzt. Das Unternehmen wird seine finanziellen Ergebnisse für das am 30. September 2024 endende Quartal vor Markteröffnung veröffentlichen.
Interessierte können über einen Live-Webcast, der auf der Investorenbeziehungswebsite des Unternehmens verfügbar ist, teilnehmen und Fragen über das Portal oder per E-Mail einreichen. Für Teilnehmer, die sich im Voraus registrieren, steht auch eine Konferenztelefonoption zur Verfügung, und eine Wiederholung wird auf der Unternehmenswebsite zugänglich sein.
- None.
- None.
CARMEL, Ind., Nov. 05, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its third quarter period ended September 30, 2024, on Tuesday, November 12, 2024, before market open. The Company has scheduled a conference call for the same day, Tuesday, November 12, 2024, at 9:00 am ET to review the results.
Conference Call Details
Date and Time: Tuesday, November 12, 2024, at 9:00am ET
Live Webcast Information: Interested parties can access the conference call via a live webcast, which is available in the Investor Relations section of the Company's website at https://edge.media-server.com/mmc/p/op4xi3gu or https://ir.neuraxis.com/. For participants listening through the webcast, questions can be sent in through the portal using the “Ask a Question” link or by emailing questions to NRXS@lythampartners.com.
Call-in Information: Interested parties can also access the live conference call by initially registering at the following link.
Upon completion of the registration link, call-in participants will receive the dial-in info and a unique PIN to join the call as well as an email confirmation with the details.
Replay: A webcast replay will be available in the Investor Relations section of the Company's website at https://edge.media-server.com/mmc/p/op4xi3gu or https://ir.neuraxis.com/.
About NeurAxis, Inc.
NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive the adoption of its IB-Stim™ therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim™ is FDA-cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 8-21 years old. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. For more information, please visit http://neuraxis.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, the conditions in the U.S. and global economy, the trading price and volatility of the Company’s stock, public health issues or other events, the Company’s compliance with applicable laws, the results of the Company’s clinical trials and perceptions thereof, the results of submissions to the FDA, the results of the shareholder vote to enable the issuance of the Preferred Stock, and factors described in the Risk Factors section of NeurAxis’s public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.
For contraindications, precaution, warnings, and IFU, please see: https://ibstim.com/important-information/.
Contacts:
Company
NeurAxis, Inc.
info@neuraxis.com
Investor Relations
Ben Shamsian
Lytham Partners
646-829-9701
shamsian@lythampartners.com
FAQ
When will NeurAxis (NRXS) report its Q3 2024 earnings?
How can investors access NeurAxis (NRXS) Q3 2024 earnings call?